News
Isis Pharmaceuticals Initiates Phase 1 Study of ISIS-DMPK Rx...
Isis Earns $14 Million Milestone Payment from Biogen Idec ISIS-DMPKRx is the Second Generation 2.5 Antisense Drug to Enter the Clinic Isis Pharmaceuticals, Inc. announced...
News
Biotech Stocks Technical Report — Research on Exact Sciences,...
On Friday, June 06, 2014, the NASDAQ Composite ended at 4,321.40, up 0.59%, the Dow Jones Industrial Average finished the day 0.52% higher at 16,924.28,...
News
Edge Therapeutics begins enrolment in second cohort of EG-1962...
US-based biotechnology firm Edge Therapeutics has started enrolling patients in the second group of a multicenter, randomised, controlled, open-label, Phase I/II NEWTON trial of its...
News
Arena begins Phase Ib trial of APD334 to treat...
US-based Arena Pharmaceuticals has started dosing patients in an investigational Phase Ib clinical trial of APD334, an oral drug candidate that targets the sphingosine 1-phosphate...
News
KIP THE HUMANS: DRUG DISCOVERY BY SIMULATING CELLS
The future of medicine, we're often told, will be personalized. We'll have gene therapies, wearables to monitor our vital signs—maybe even new kinds of vital...
News
AstraZeneca’s Bydureon achieves better glycaemic control than insulin glargine...
UK-based AstraZeneca has reported results from its longest, randomised, head-to-head DURATION-3 trial of exenatide once-weekly, a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist used to treat...
News
Boston Therapeutics begins Phase IIb Sugardown trial for type...
US-based Boston Therapeutics (BTI) has started a Phase IIb clinical trial SD-002 to evaluate the efficacy and safety of Sugardown in patients with type 2...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.